Stock Analysts

J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment

Johnson & Johnson ’s JNJ subsidiary, Janssen Biotech announced that the FDA has approved its new drug application (NDA) for apalutamide for the treatment of men with non-metastatic castration-resistant prostate cancer (“nmCRPC”). Apalutamide, J&J’s next-generation oral androgen receptor (“AR”) inhibitor, will be marketed under the trade name of Erleada. The FDA decision comes much earlier than expected. […]

Stock Analysts

EQT Corp (EQT) Beats Earnings and Revenues Estimates in Q4

EQT Corporation EQT posted fourth-quarter 2017 adjusted earnings per share of 76 cents, beating the Zacks Consensus Estimate of 22 cents. The figure also increased 204% from 25 cents in the year-earlier quarter. In 2017, the company reported adjusted earnings of $1.47 per share, which beat the Zacks Consensus Estimate of 79 cents. […]

Stock Analysts

5 Top Momentum Stocks to Buy as Market Bounces Back

Wall Street showed a strong revival from the vicious sell-off seen last week, with major indices back in the green territory for the year. Both the Dow Jones Industrial Average and the S&P 500 Index climbed for the fourth consecutive session, surging at least 4.5% each. In fact, the S&P 500 index witnessed the strongest four-day performance since mid-2016. […]

Mergers & Acquisitions

Fieldwood Energy Files Prepackaged Chapter 11 Cases and Announces Gulf of Mexico Acquisition

Fieldwood Energy Files Prepackaged Chapter 11 Cases and Announces Gulf of Mexico Acquisition PR Newswire HOUSTON, Feb. 15, 2018 HOUSTON , Feb. 15, 2018 /PRNewswire/ — Fieldwood Energy LLC (together with its subsidiaries and certain affiliates, the “Company” or “Fieldwood”) announced today that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the Bankruptcy Court for the Southern District of Texas as part of a “prepackaged” chapter 11 case. […]

Stock Analysts

Equinix (EQIX) Tops Q4 AFFO & Revenue Estimates, Guides Well

Equinix Inc. EQIX posted better-than-expected fourth-quarter 2017 results, wherein the top and bottom lines surpassed the Zacks Consensus Estimate and increased from the year-ago quarter as well. The company’s adjusted funds from operations (AFFO) advanced from $4.08 per share reported in the year-ago quarter to $4.82 per share. […]

Stock Analysts

Soft North American Sales to Hit Coca-Cola (KO) Q4 Earnings

Revenues of The Coca-Cola Company ’s KO North America segment, comprising about 30% of its topline, are expected to decline in the fourth quarter of 2017, when it reports on Friday, Feb 16. A Look at Coca-Cola’s North America Performance in Q3 The North America segmental revenues totaled $2.75 billion last quarter, increasing 3% year over year on 2% growth in price/mix. Organically, revenues rose 2% in the period while volumes remained unchanged during the same. […]

Stock Analysts

Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

Zoetis Inc. ZTS posted fourth-quarter 2017 adjusted earnings of 69 cents per share (excluding one-time items and a provisional net tax charge of $212 million related to recently enacted tax legislation in the United States) increased 47% year over year and beat the Zacks Consensus Estimate of 66 cents. Total revenues rose 14% year over year (up 13% operationally excluding the impact of currency) to $1.5 billion in the quarter and beat the Zacks Consensus Estimate of $1.40 billion […]